WallStSmart

Novartis AG ADR (NVS)vsPark Dental Partners, Inc. Common Stock (PARK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 22454% more annual revenue ($56.69B vs $251.37M). NVS leads profitability with a 22.5% profit margin vs -1.4%. NVS earns a higher WallStSmart Score of 51/100 (C-).

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96

PARK

Avoid

28

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 5.0Quality: 3.5
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-47.0%)

Margin of Safety

-47.0%

Fair Value

$93.29

Current Price

$137.16

$43.87 premium

UndervaluedFair: $93.29Overvalued

Intrinsic value data unavailable for PARK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$260.70B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

PARK1 strengths · Avg: 8.0/10
Free Cash FlowQuality
$2.24B8/10

Generating 2.2B in free cash flow

Areas to Watch

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
3.222/10

Expensive relative to growth rate

PARK4 concerns · Avg: 2.8/10
Market CapQuality
$97.15M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
1.9%3/10

Operating margin of 1.9%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-18.6%2/10

ROE of -18.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bull Case : PARK

The strongest argument for PARK centers on Free Cash Flow.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Bear Case : PARK

The primary concerns for PARK are Market Cap, Operating Margin, Piotroski F-Score. Debt-to-equity of 2.02 is elevated, increasing financial risk.

Key Dynamics to Monitor

NVS profiles as a value stock while PARK is a turnaround play — different risk/reward profiles.

PARK is growing revenue faster at 5.1% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 28/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Park Dental Partners, Inc. Common Stock

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Park Dental Partners, Inc. is a dental resource organization that offers business support services to dentists throughout Minnesota and Wisconsin. The company is headquartered in Roseville, Minnesota.

Visit Website →

Want to dig deeper into these stocks?